S0405 - European Medicines Agencies Network strategy to 2028: Spotlight on Innovation & Competitiveness

Wed, Mar 19, 2025 · 8:30–9:40 AM CET Singapore Room, Congress Center Basel

About this session

This session will update on the status of implementation of the European Medicines Agencies Network Strategy so far and provide an outlook to 2028 in the area of innovation & competitiveness.

Participants will hear from EMA and HMA on the state of play and planned future activities in this area and gain insights on the perspective and expectation of stakeholders, including patient representatives and industry.

Programme:
- Panel Discussion — Nikos Dedes, Katrin Rupalla, Beata Stepniewska
- 1. Regulatory Science, Innovation and Competitiveness — Falk Ehmann, María Lamas

Speakers

Beata Stepniewska

Deputy Director , Head of Regulatory Affairs · Medicines for Europe

Panelist
Nikos Dedes

General Secretary · Greek Patients Association

Panelist
Falk Ehmann

Head Innovation and Development Accelerator · European Medicines Agency

Speaker
María Lamas

Executive Director · Spanish Agency for Medicines and Medical Devices (AEMPS)

Speaker
Katrin Rupalla

Head of Global Regulatory Affairs · Johnson & Johnson (J&J) Innovative Medicine

Panelist
Rui Santos Ivo

President of the Executive Board · INFARMED - National Authority of Medicines and Health Products, I.P.

Chair
Melanie Carr

Head of Stakeholders and Communication Division · European Medicines Agency

Chair